Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis

[1]  S. Mackinnon,et al.  Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services , 2018, British journal of haematology.

[2]  S. Schrier,et al.  Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. , 2017, Blood.

[3]  P. Neri,et al.  Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? , 2017, Bone Marrow Transplantation.

[4]  A Orfao,et al.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma , 2017, Leukemia.

[5]  M. Gertz,et al.  First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. , 2016, Blood.

[6]  M. Liedtke,et al.  First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[8]  A. Órfão,et al.  Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. , 2016, Blood.

[9]  F. Prósper,et al.  Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. , 2016, Blood.

[10]  M. Dimopoulos,et al.  Recent advances in the management of AL Amyloidosis , 2016, British journal of haematology.

[11]  D. Hose,et al.  Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Hose,et al.  Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Ocio,et al.  The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. , 2011, Blood.